The deuterated pyrazoloquinolinone targeting α6 subunit-containing GABAA receptor as novel candidate for inhibition of trigeminovascular system activation: implication for migraine therapy
These results suggest that DK-I-56-1 is a promising candidate for novel migraine pharmacotherapy, through positively modulating TG α6GABA<sub>A</sub>Rs to inhibit TGVS activation, with relatively favourable pharmacokinetic properties.
Authors
- James M. Cook (ORCID: https://orcid.org/0000-0001-5512-3022)
- Ming Tatt Lee (ORCID: https://orcid.org/0000-0003-3957-2439)
- Pi‐Chuan Fan (ORCID: https://orcid.org/0000-0002-6974-971X)
- Tzu-Hsuan Lai
- Lih‐Chu Chiou (ORCID: https://orcid.org/0000-0001-5356-940X)
- Dishary Sharmin (ORCID: https://orcid.org/0000-0003-0417-4262)
Institutions
- National Taiwan University (TW)
- China Medical University (TW)
- National Taiwan University Hospital (TW)
- University of Wisconsin–Milwaukee (US)
- UCSI University (MY)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-08-26
- DOI
- https://doi.org/10.3389/fphar.2024.1451634
- Citations
- 5
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.93
Funders
- National Science Foundation
- Ministry of Higher Education, Malaysia
- National Health Research Institutes
- National Taiwan University Hospital
- National Taiwan University
- National Science and Technology Council
- National Institutes of Health
- Division of Chemistry